Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women

Sponsor
Novo Nordisk A/S
Study ID
NCT01508858
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
  • placebo — DRUG
    Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
  • levonorgestrel / ethinylestradiol — DRUG
    One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period

Study Details

This trial is conducted in Europe. The aim of this trial is to investigate if liraglutide changes AUC (area under the curve) of ethinylestradiol and levonorgestrel administered as a combination contraceptive drug (Neovletta®).

Key Dates

Start date
Nov 30, 2006
Status verified
Jan 2017
Primary completion
Apr 30, 2007
Completion
Apr 30, 2007

Study Design

Enrollment
21 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment period 1
  • Placebo Comparator: Treatment period 2

Primary Outcome Measure

AUC of ethinylestradiol

Related Studies